[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Blueprint](https://github.com/mm80843/T3.5/tree/main/docs/Blueprint/index.md) >> Individual ID:PBN__aBlueprint_29 

# __Implementing Pooled-Sample Analysis and Contact Tracing Systems__

## 0. Blueprints points to this category of risks

* [The challenges include inadequate monitoring and contact tracing, limited sensor diversity, and temporary regulations to restrict activities in public places.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_66.md)

## 1. Summary of the blueprint

* The presented blueprint aims to address risks associated with the monitoring, contact tracing, and testing of contagious diseases within green building neighborhoods. Green building neighborhoods comprise structures designed with considerations for energy efficiency and environmental sustainability. Therefore, this context adds unique challenges to disease control due to the integrated dynamics of people, infrastructures, and the extra added layers of green technologies. These instances pose a critical demand for effective strategies and technologies to achieve effective disease management and population safety within such spaces.

* The nature of the risks considered within this blueprint primarily focuses on the deficiencies in disease detection, diagnostics, and monitoring. These span the gamut from discord in contact tracing capabilities, limited diagnostic testing capacities, to disruptions to surveillance systems. Among the foremost concerns noted are the insufficiencies in equipment, lack of interoperability, as well as misdiagnoses due to incomplete detection. Such risks potentially impair the capacity for disease containment, thereby augmenting the potential impacts within green building neighborhoods due to the dense population intermingling.

* Mitigation measures captured within the blueprint are comprised of progressive actions and technological means designed to enhance the capacity for disease containment. The measures involved prioritize essential research, augmented testing capacities, and the further development of remote monitoring. Identification and prioritizing pools for sample analysis, introducing widespread symptom testing and monitoring, in addition to innovating rapid and accurate testing kits, form part of these initiatives. Simultaneously, the harnessing of the intensive use of digital tools for contact tracing is also encouraged.

* The execution of this mitigation blueprint offers substantial benefits in proactive disease control within green building neighbourhoods. Key among these is the early detection of disease outbreaks, which facilitates timely intervention in disease spread. Additionally, this blueprint allows for an enhanced surveillance approach, covering populations within the identified areas. Moreover, it promotes the adoption of innovative technologies which not only boost disease detection and diagnosis but also herald advancements in public health efforts. The expected outcome is a safer, healthier population within these unique living and working spaces.

## 2. Details of the blueprint

* I recommend implementing the 'Blueprint' in your green building neighbourhoods. In basic terms, the 'Blueprint' is a set of steps, actions, and technologies aimed at improving the detection, control, and management of contagious diseases within these green environments. It includes methods to enhance contact tracing and diagnostic testing capacities through the use of digital tools, improving symptom monitoring, accelerating the production of accurate testing kits and prioritising research. By following these steps, we can handle any disease outbreak more effectively and maintain the health of the population within green buildings while keeping everyone safe.

* Government authorities, healthcare organisations, and owners of public spaces within green building neighbourhoods can implement the 'Blueprint'.

* 'Neighbourhood'

* The 'Blueprint' lists several risks associated with controlling contagious diseases in green building neighbourhoods such as difficulties in contact tracing, limited testing capacity, and disruptions in surveillance systems. All these could lead to issues such as incomplete disease detection, misdiagnosis, and ineffective management of disease outbreaks.

## 3. Blueprint impacts these stakeholders

* [General population](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_9.md)
* [General public](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_73.md)
* [Government](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_29.md)
* [Healthcare organizations](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_216.md)
* [Visitors to public places](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_765.md)

## 4. Blueprint links to these mitigations

* [Implement regular and widespread symptom monitoring and testing, both symptomatic and asymptomatic](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_2722.md)
* [Improve contact tracing systems, increase testing capacity, utilize digital tools for contact tracing](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_2842.md)
* [Increase testing capacity, develop rapid and accurate test kits, promote widespread testing](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_2720.md)
* [Pooled-sample analysis](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_2036.md)
* [Prioritize essential research and monitoring activities, develop remote monitoring techniques, enhance capacity-building efforts](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_1021.md)

## 5. Blueprint mitigation can be owned by these stakeholders

* [Diagnostic test manufacturers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_73.md)
* [Government](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_216.md)
* [Government authorities](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_302.md)
* [Healthcare organizations](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_766.md)
* [Public place owners](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_1388.md)

## 6. Blueprint links to these benefits

* [Early detection of covid-19](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_988.md)
* [Early warning of disease outbreaks](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_5.md)
* [Population-wide surveillance](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_1206.md)

## 7. Blueprint links to these technology

* [Analytical chemistry](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_2468.md)
* [Iot](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_2669.md)
* [Pcr assay](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_2670.md)
* [Qrt pcr testing](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_2821.md)
* [Quantitative rt-pcr methodology](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_2822.md)
* [Rt-qpcr assay](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_3066.md)
* [Sewage monitoring](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_3067.md)
* [Wastewater analysis](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_3129.md)
* [Wastewater sampling](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_3130.md)
* [Wastewater testing](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_277.md)

